Details of the Drug Combination

General Information of Drug Combination (ID: DCTZF98)

• Drug Combination Name: BHV-0223 + Pyronaridine
• Indication: DD2; Status: Investigative [1]
• Component Drugs:
  BHV-0223 (DMBLM5H): N.A.
  Pyronaridine (DMUWAM2): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: DD2
  Zero Interaction Potency (ZIP) Score: 1.371
  Bliss Independence Score: 4.178
  Loewe Additivity Score: 1.155
  LHighest Single Agent (HSA) Score: 2.14

Molecular Interaction Atlas of This Drug Combination

Indication(s) of BHV-0223

Disease Entry	ICD 11	Status	REF
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[2]

Indication(s) of Pyronaridine

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[3]

Pyronaridine Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	TTZVSJ2	NOUNIPROTAC	Inhibitor	[4]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.